Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Vinge hones its offering within capital requirements and risk management in the financial services sector

In order to further strenghthen its service offering within the Banking & Finance and Regulatory practice area, Vinge has formed a team within the capital requirements and risk management in the financial services sector. Torbjörn Jacobsson, whose background includes, among other things, head of risk in the banking sector, has been recruited to lead the group as a senior specialist in relation to issues concerning financial risks and capital requirements.
November 30, 2021

Emelie Svensäter Jerntorp appointed as new partner

Commencing 1 January 2022, Emelie Svensäter Jerntorp will become a partner at Vinge’s Skåne office.
November 19, 2021

Sweden proposes a new law on investment screening which will have significant implications for transactions

Contrary to the situation in many other countries, there are currently only limited possibilities to regulate or prevent foreign direct investments in Sweden that could entail risks to Swedish security interests. Existing regulatory frameworks, such as the Protective Security Act (Sw. Säkerhetsskyddslagen), are limited to certain areas, to certain activities and to specific situations. The final report of the Inquiry of foreign direct investments (Sw. Granskning av utländska direktinvesteringar), published on 1 November 2021, puts forward a proposal for new legislation to address this gap.
November 04, 2021